Podcasts about Nature Biotechnology

Even though it was completed a quarter century ago, geneticists still struggle to estimate the number of genes in the human genome. They went from ‘hundreds of thousands' to “22 thousand”, then more recently to “about 19,500”. The number, however, has just exploded. Tens of thousands of new genes with important functions were discovered hiding in the ‘junk DNA'. Dr Rob explains what these new findings mean to the creation-evolution debate. Links and notes: Carter 2025 The dark proteome https://creation.com/dark-proteome Carter 2024 The incredible shrinking human genome, https://biblicalgenetics.com/shrinking-genome/ Amaral et al. 2024 The status of the human gene catalogue, Nature 622(7981):41–47; https://pubmed.ncbi.nlm.nih.gov/37794265/ Prensner et al. 2024 What can Ribo-seq and proteomics tell us about the non-canonical proteome? https://www.biorxiv.org/content/10.1101/2023.05.16.541049v1 Pennisi 2024 ‘Dark proteome' survey reveals thousands of new human genes, Science 386(6725):951–952; https://pubmed.ncbi.nlm.nih.gov/39607933/ Podcast: https://biblicalgenetics.com/contra-creation-myths Carter et al. 2004 Cloning of anthozoan fluorescent protein genes, Comparative Biochemistry and Physiology, Part C 138:259–270; https://pubmed.ncbi.nlm.nih.gov/15533784 Matz et al. 1999 Fluorescent proteins from nonbioluminescent Anthozoa species, Nature Biotechnology 17(10):969–973; https://pubmed.ncbi.nlm.nih.gov/10504696/

This show is going to be a little bit different because what we're going to do today is offer some advice to those who may work at a pharma company. But before we get into this advice portion of the discussion, let's start here. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Probably we're gonna have people listening to this episode who maybe are not in our normal tribe of Relentless Health Value listeners. While there are, for sure, regular listeners who work at pharma companies, there might be some newbies on the scene here. And to you, I say welcome. I hope that you feel right at home here. You know what, though? Many of us, including myself often enough, are slightly uncomfortable. Because this is the place where we all kind of look at ourselves in the mirror. We all live in glass houses, after all—everyone in the healthcare industry. There's no devils and no angels here. And the trick is maximizing the good and minimizing the not so good so that we all wind up with the highest net positive possible for patients. So, around here, we do not shy away from saying what needs to be said so that we all can find a way forward to serve the patient. We cannot solve problems, after all, that we have not taken a cold, hard look at. Yeah. So, today I am speaking with Brian Reid. I have been very much looking forward to speaking with Brian Reid, who many may know from his really great newsletter and really insightful LinkedIn posts. Brian Reid's advice, which he delivers in the episode that follows in sum. Spoiler alert here, but I also will say that he is much more eloquent than me, and the nuances are a thing. So, please do listen to the whole show. But Brian's piece of advice number one for Pharma (and really any product or service frankly), but piece of advice number one is this: Get a really solid bead on what value means—not just to PBMs (pharmacy benefit managers) or contract pharmacies or wholesalers who are middlemen but to the ultimate purchasers, the ones whose wallets the money is actually coming out of to pay the bill. Meaning, plan sponsors, such as self-insured employers or unions, patients themselves or members, and taxpayers. Again, how does value accrue to the ultimate purchasers like plan sponsors, patients/members, or taxpayers? Everybody else in the drug supply chain, let's be clear, is in the middle pushing money around that came out of somebody else's wallet. These middlemen have their own interests that may, for sure, may or may not be aligned with the interests of the ultimate purchasers. Getting value realized by patients will depend on understanding what the value is to these ultimate purchasers and then not getting derailed by any middleman who may not be so aligned. As a sidebar on this number one piece of advice, the whole “what's your value” and influence coloring this value equation made by ultimate purchasers is the prevailing beliefs of these ultimate purchasers, relative to Pharma, how they perceive the pharma industry. Whether it's earned or not—and this is not what we're gonna discuss today—but earned or not, Pharma does not have a great reputation with these folks right now. And this matters. Brian has a lot to say on this topic, which is fascinating. So, you should listen. Number two piece of advice that Brian Reid delivers in the podcast that follows that we talk about: Consider inching into the fray around benefit design. Rightfully so, there's always a lot of talk about patient affordability at pharma companies; but if I was gonna point to one thing that impacts affordability more than anything else, it'd be benefit design. There's only a small, underfunded cadre right now of folks out there (Mark Cuban aside, actually); but there's only a really small number of folks who never have any money who are really helping plan sponsors understand the impact on patients of some of the choices that they are making. I mean, personally, I could think of 10 things to do right off the top of my head that could help plan sponsors not get inadvertently screwed in this realm alone, just thinking they're saving money when, in reality, they are harming patients and not saving money. There's probably a lot of opportunities to communicate these kinds of things that are really win-win collaborations. Number three piece of advice that we talk about in the conversation that follows with Brian Reid: Keep an eye on hospital consolidation and vertical integration in the payer space. Consolidation raises prices and impedes patient affordability. This is as per study after study after study. Consolidation raises prices and sometimes considerably. Here's a part B to this third piece of advice about consolidation. There's sometimes wild swings in prices at different large, consolidated health systems in the exact same geography. Listen to the show with Cora Opsahl (EP452) for more about how their health plan, as just one example, saved $30 million a year just pushing a huge expensive health system, consolidated one, out of their network and navigating patients to more affordable sites of care. This matters to pharma companies because hospital system prices are currently crushing in many areas of the country, really impacting patient affordability. But there are better or worse options from an affordability standpoint in some of these geographies. To state the obvious, if an infusion of the same drug costs 10 times more if a patient shows up in one care setting versus another, that latter place, not affordable for patients. And by the way, that is not hyperbole of any kind. There are plenty of examples where literally an infusion of the same drug, same dosage will cost 10 times more if a patient goes one place versus another. But, again, it's not affordable. The patient cost share might be 10 times higher if it's coinsurance, if the patient goes to that latter place. And that latter 10x more of the cost place also just added 10x the cost to the PAP program or the foundation debit column. All of this is really relevant to Pharma. And just to pile on here because now I'm on a roll, another reason why this matters, these striking price variations between care settings, if we're talking about product value, and if the price the patient or the plan sponsor is paying is 10x the cost of the ingredients, nobody's doing that math and separating out the cost of ingredients from the, you know, total cost of the infusion. It is one lump sum number. So, if we're defining value as outcomes divided by cost and now the cost to the plan sponsor is 10x, product value just got reduced by 10x. Just in case anyone is confused here, and you probably know this, but many forget that the whole ASP (average selling price) plus 6% provider reimbursement—so, if that's what you're thinking and you're wondering how the 10x transpires—that ASP plus 6% provider reimbursement is only for Medicare kinds of plans. Hospitals can and do negotiate much higher reimbursements for commercial plans, and those carriers that have commercial lines of business and also MA (Medicare Advantage) books of business even allegedly actually negotiate higher commercial reimbursements so that they can get lower Medicare Advantage rates. Right, and you can see why, because the MA dollars are coming out of their own capitated pockets, whereas the commercial rates are being paid for by the ultimate purchasers, the plan sponsors. Also mentioned in this episode are Reid Strategic; Mark Cuban; Cora Opsahl; Bruce Rector, MD; Shawn Gremminger; Nina Lathia, RPh, MSc, PhD; Autumn Yongchu; Erik Davis; and Marty Makary, MD, MPH. Additional related episodes: EP380 with Mark Miller, PhD, on pharma communications. EP371 with Erik Davis and Autumn Yongchu on buy and bill versus pharmacy bagging. EP426 with Nina Lathia, RPh, MSc, PhD, on cost containment versus value-based drug purchasing. EP435 with Dan Mendelson from Morgan Health on how employers should consider pharma purchasing. EP365 with Scott Haas on PBM contracts and drug rebates. EP293 with Dea Belazi, PharmD, MPH, from AscellaHealth on co-pay cards, co-pay accumulators, and co-pay maximizers.   You can learn more by subscribing to Brian's newsletter and by following him on LinkedIn.   Brian Reid has nearly three decades of experience in healthcare journalism, public affairs, and public relations with a specialty in explaining the economics of the healthcare system. He is the founder of Reid Strategic, a communications consultancy, and a senior fellow at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center. At Reid Strategic, Brian counsels industry leaders on the best way to communicate on complex policy, access, pricing, and reimbursement issues in ways that critical audiences can understand. Brian's core belief is that we can't build a better healthcare system until everyone understands the system we have today. Reid Strategic offers communications strategy and execution around corporate, brand, and policy challenges, from prelaunch approaches to lifecycle management. Prior to founding Reid Strategic, Brian built and led Real Chemistry's Value+Access Communications practice, the largest such group dedicated to issues of value. Brian has written extensively for a range of audiences. At Reid Strategic, he publishes the daily Cost Curve newsletter; and his past experience includes coverage of the health science/policy beat for Bloomberg News, creation of patient education materials for the National Institutes of Health, and features in publications ranging from the Washington Post to Nature Biotechnology to Men's Health. He has a bachelor's degree in biology and political science from Emory University and a master's degree from the Columbia University School of Journalism.   08:29 Why is it important to understand the term “value” in respect to medicine? 10:07 Why is it important to consider all the players affected by the idea of this “value”? 11:06 Who are the ultimate purchasers in Pharma? 12:23 Findings of the Kaiser Employer Health Benefits Survey. 14:52 Why does it matter that we consider what value looks like to all players affected by Pharma? 16:46 EP300 with Bruce Rector, MD. 18:38 EP448 (Part 1) with Shawn Gremminger. 20:04 What does Pharma need to do to showcase their value when PBMs are often “locked in” at the moment? 23:11 Why Brian is celebrating companies that put their prices in their press releases. 32:31 Why does Pharma have an obligation to explain their value? 33:16 EP426 with Nina Lathia, RPh, MSc, PhD. 33:39 Why is it important for Pharma to keep an eye on hospital monopoly behavior? 35:55 EP370 with Erik Davis and Autumn Yongchu. 37:44 Why Pharma needs to capitalize on alignment.   You can learn more by subscribing to Brian's newsletter and by following him on LinkedIn.   Brian Reid, of Reid Strategic, discusses #pharma and #patientaffordability on our #healthcarepodcast. #healthcare #podcast #financialhealth #primarycare #patientoutcomes #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Dr Beau Raymond, Brendan Keeler, Claire Brockbank, Cora Opsahl, Dan Nardi, Dr Spencer Dorn (EP451), Marilyn Bartlett, Dr Marty Makary, Shawn Gremminger (Part 2), Shawn Gremminger (Part 1), Elizabeth Mitchell (Summer Shorts 9)  

This podcast episode features a discussion on the ethical development and use of AI in the field of Applied Behavior Analysis (ABA). The panel, consisting of CentralReach subject matter experts, explores the potential benefits and challenges of integrating AI into ABA practice. They share insights on how AI can be used to enhance efficiency, support clinical decision-making, and maintain high ethical standards. The conversation also expounds upon the importance of transparency, client consent, and the evolving role of behavior analysts in the context of advancing technologies.  To earn CEUs for listening, click here, log in or sign up, pay the CEU fee, + take the attendance verification to generate your certificate! Don't forget to subscribe and follow and leave us a rating and review. Show Notes References and Resources:      American Nurses Association, ANA Center for Ethics and Human Rights, (2022). The ethical use of artificial intelligence in nursing practice. www.nursingworld.org CentralReach (2024). Ethical AI integration in ABA: A framework for success. https://www.youtube.com/watch?v=uyvBEuUfRbA Cedars Sinai, (2024). Pursuing the ethics of artificial intelligence in healthcare. https://www.cedars-sinai.org/newsroom/pursuing-the-ethics-of-artificial-intelligence-in-healthcare/ Cox, D. J., & Jennings, A. M. (2024). The promises and possibilities of artificial intelligence in the delivery of behavior analytic services. Behavior Analysis in Practice, 17, 123-136. Beam, A. L., & Kohane, I. S. (2018). "Big data and machine learning in health care." JAMA, 319(13), 1317-1318. Ford, E., et al. (2016). "Extracting information from the text of electronic medical records to improve case detection: a systematic review." Journal of the American Medical Informatics Association, 23(5), 1007-1015. Ghafghazi, S., Carnett, A., Neely, L., Das, A., & Rad, P. (2021). AI-Augmented behavior analysis for children with developmental disabilities. Cybernetics Magazine, Vol (10). Grote, T., & Berens, P. (2023). A paradigm shift? On the ethics of medical large language models. Bioethics, 38, 38-390. DOI: 10.1111/bioe.13283 Hosny, A., et al. (2018). "Artificial intelligence in radiology." Nature Reviews Cancer, 18(8), 500-510. Panesar, S., et al. (2019). "Machine learning in neurosurgery: a systematic review." Neurosurgical Focus, 46(5), E2. Rajkomar, A., et al. (2018). "Scalable and accurate deep learning with electronic health records." NPJ Digital Medicine, 1(1), 1-10. Schork, N. J. (2019). "Artificial intelligence and personalized medicine." Cancer Treatment and Research, 178, 265-283. Sheikhalishahi, S., et al. (2019). "Natural language processing of clinical notes on chronic diseases: Systematic review." JMIR Medical Informatics, 7(2), e12239. Stade, E.C., Stirman, S. W., Ungar, L., Boland, C. L., Schwartz, H. A., Yaden, D. B., Sedoc, J., DeRubeis, R. J., Willer, R., Kim, J. P., & Eichstaedt, J.C. (2024). Toward responsible development and evaluation of LLMs in psychotherapy. Stanford University:Human-Centered Artificial Intelligence https://hai.stanford.edu/sites/default/files/2024-06/HAI-Policy-Brief-Responsible-Development-LLMs-Psychotherapy.pdf Topol, E. J. (2019). "High-performance medicine: the convergence of human and artificial intelligence." Nature Medicine, 25(1), 44-56. Torous, J., & Hsin, H. (2018). "Empowering the digital therapeutic relationship: virtual clinics for digital health interventions." NPJ Digital Medicine, 1(1), 1-3. Zhavoronkov, A., et al. (2019). "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." Nature Biotechnology, 37(9), 1038-1040.

A client uses fentanyl patches to manage chronic pain from a back injury. What kind of risk does this present to the therapist? And, if we're not careful, the bigger risk might be to the client. Check it out on this episode of “I Have a Client Who . . .” with Ruth Werner. Resources:   Cai, B., Engqvist, H. and Bredenberg, S. (2015) ‘Development and evaluation of a tampering resistant transdermal fentanyl patch', International Journal of Pharmaceutics, 488(1), pp. 102–107. Available at: https://doi.org/10.1016/j.ijpharm.2015.04.061. Commissioner, O. of the (2023) ‘Accidental Exposures to Fentanyl Patches Continue to Be Deadly to Children', FDA [Preprint]. Available at: https://www.fda.gov/consumers/consumer-updates/accidental-exposures-fentanyl-patches-continue-be-deadly-children (Accessed: 4 April 2024). ‘Drug Overdoses - Data Details' (no date) Injury Facts. Available at: https://injuryfacts.nsc.org/home-and-community/safety-topics/drugoverdoses/data-details/ (Accessed: 4 April 2024). Duragesic Transdermal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD (no date). Available at: https://www.webmd.com/drugs/2/drug-14008/duragesic-transdermal/details (Accessed: 4 April 2024). Ep 186 – Fentanyl Patches: “I Have a Client Who . . .” Pathology Conversations with Ruth Werner (2022) Associated Bodywork & Massage Professionals. Available at: https://www.abmp.com/podcasts/ep-186-fentanyl-patches-i-have-client-who-pathology-conversations-ruth-werner (Accessed: 4 April 2024). Equity--OS-OPAE--1600, O. of P.A. and (no date) Fentanyl Exposure in Public Places | Washington State Department of Health. Available at: https://doh.wa.gov/community-and-environment/opioids/fentanyl-exposure-public-places (Accessed: 4 April 2024). Fentanyl Facts (2024). Available at: https://www.cdc.gov/stopoverdose/fentanyl/index.html (Accessed: 4 April 2024). Khan, S. and Sharman, T. (2024) ‘Transdermal Medications', in StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK556035/ (Accessed: 4 April 2024). Kim, T.S. et al. (2015) ‘Comparison of adhesion and dissolution of fentanyl patches: Fentadur® and Durogesic DTrans®', Journal of Pharmaceutical Investigation, 45(5), pp. 475–480. Available at: https://doi.org/10.1007/s40005-015-0195-y. Mann, B., News, A.P.-K.H. and Bebinger, M. (2023) ‘In 2023 fentanyl overdoses ravaged the U.S. and fueled a new culture war fight', NPR, 28 December. Available at: https://www.npr.org/2023/12/28/1220881380/overdose-fentanyl-drugs-addiction (Accessed: 4 April 2024). Overdose (no date) Drug Policy Alliance. Available at: https://drugpolicy.org/overdose/ (Accessed: 5 April 2024). Prausnitz, M.R. and Langer, R. (2008) ‘Transdermal drug delivery', Nature Biotechnology, 26(11), pp. 1261–1268. Available at: https://doi.org/10.1038/nbt.1504. Shearn, I.T. (2023) Fentanyl myth: Police cry overdose, facts prove otherwise, NJ Spotlight News. Available at: https://www.njspotlightnews.org/special-report/fentanyl-myth-police-cry-overdose-facts-prove-otherwise/ (Accessed: 5 April 2024). Using Skin Patch Medicines Safely (no date). Available at: https://www.poison.org/articles/using-skin-patch-medicines-safely (Accessed: 4 April 2024). Wong, W.F. et al. (2023) ‘Recent Advancement of Medical Patch for Transdermal Drug Delivery', Medicina, 59(4), p. 778. Available at: https://doi.org/10.3390/medicina59040778.   Host:   Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.        Sponsors:   Books of Discovery: www.booksofdiscovery.com     Anatomy Trains: www.anatomytrains.com    Elements Massage: www.elementsmassage.com/abmp   Earthlite: www.earthlite.com

On our very first episode of the new podcast series from Nature Biotechnology, our Associate Editor Cláudia Vilhena interviews Marcus Walker, first author of a fantastic story on engineered bacteria used to stain textiles.With an informal and honest touch, Marcus and Cláudia dive into the behind the scenes of the paper. From the inspiration to combine microbiology and fashion, passing by what went wrong at the bench, all the way to the economical and environmental implications of living biomaterials.For all those who struggle with measuring optical density, this episode is for you! Hosted on Acast. See acast.com/privacy for more information.

In this episode, I interviewed Dr. Antentor Hinton Jr. Per his biosketch on his lab website, he is a tenure-track Assistant Professor in the Department of Molecular Physiology and Biophysics in the Vanderbilt School of Medicine Basic Sciences at Vanderbilt University and a member of the Vanderbilt Diabetes Research and Training Center and the Ernest E. Just Early Career Investigator. Dr. Hinton's laboratory has a strong commitment to diversity. Dr. Hinton has published 8 STEM education papers and 32 diversity, equity, inclusion, mentoring, and career development commentaries. Dr. Hinton is currently a national leader on matters related to diversity, equity, inclusion and mentoring. Some of Dr Hinton's publications include Cell, 2023 (First DEI cover article), Cell, 2022, Cell, 2020, EMBO, 2020 (a), EMBO 2020 (b) Nature Biotechnology, 2020, Trends in Cancer, 2021, Trends in Biochemical Sciences, 2021, Trends in Biochemical Sciences 2022, Cell Reports Medicine, 2021 (Shared 2nd Anniversary Cover), Cell Reports Medicine, 2022, Trends in Immunology 2022, Trends in Cell Biology 2022 (a), Trends in Cell Biology (b), Trends in Biochemical Sciences, 2022 (First DEI/career development cover article for a scientific journal), Trends in Plant Sciences, 2022 (Second DEI/Career development cover article for a scientific journal, Trends in Parasitology, 2022 (Third DEI/Career development cover article for a scientific journal), Trends in Chemistry, 2023 (Fourth DEI/Career Development cover article for a scientific journal) and Trends in Pharmacological Sciences, 2022 (First mentoring cover article for a scientific journal). These pieces are constructive and heavily use the literature to make recommended suggestions. --- Send in a voice message: https://podcasters.spotify.com/pod/show/fromwheredoesitstem/message

Dr. Omid Veiseh, Ph.D. ( https://profiles.rice.edu/faculty/omid-veiseh ) is Associate Professor in the Department of Bioengineering, CPRIT Scholar in Cancer Research and Director of the Biotech Launch Pad at Rice University ( https://biotechlaunchpad.rice.edu/ ), where he leads a research program aimed at engineering next-generation treatments for a wide range of human diseases by leveraging the latest techniques in synthetic biology, immuno-engineering, and materials science to develop innovative cell-based platforms for real-time production of biologics. He is also a serial entrepreneur who has co-founded Sigilon Therapeutics (Nasdaq:SGTX), Avenge Bio, Sentinel Bio, and Curada Bio. These companies collectively have attracted ~ US$500M in private and public investment capital. Dr. Veiseh received a dual Ph. D. in Materials Science & Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Daniel G. Anderson at MIT and Harvard Medical School. Throughout his career, he has authored or co-authored more than 75 peer-reviewed publications, including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, and Natural Biomedical Engineering. He is an inventor of more than 40 pending or awarded patents. Dr. Paul Wotton, Ph.D. ( https://biotechlaunchpad.rice.edu/paul-w ) is Rice Biotech Launchpad, Executive Director. Dr. Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, named inventor and entrepreneur. He has extensive experience in strategic growth management, business transactions and product development. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL), Cynata Therapeutics (ASX: CYP), Kytopen (Chairman), Combined Therapeutics and is a Co-Founder and Director of Avenge Bio., a clinical stage biotechnology company. Dr. Wotton was President and CEO of Ocata Therapeutics (NASDAQ:OCAT) until its acquisition by Astellas Pharma in 2016. Paul was named as a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014. Support the show

Die Themen in den Wissensnachrichten: +++ Kleine Gruppen sind kreativer als große +++ Weiterer möglicher Biomarker für Long Covid +++ Babyrobben-Boom auf Helgoland +++**********Weiterführende Quellen zu dieser Folge:It takes two to think/ Nature Biotechnology, 08.01.2024Persistent complement dysregulation with signs of thromboinflammation in active Long Covid/ Science, 19.01.2024Public preference for the rewilding framework: A choice experiment in the Oder Delta/ People and Nature, 21.01.2024Megalodon body form/ Palaeontologie Electronica, Januar 2024SATB2 organizes the 3D genome architecture of cognition in cortical neurons/ Molecular Cell, 19.01.2024Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: Tiktok und Instagram.

I'm away this week.  Here's one of my favourite episodes to tide you over until I'm back. Agriculture technology is helping to fight COVID-19 and play a role in preparations for future pandemics. A recent article in Nature Biotechnology said the current pandemic shows the need to mobilize efforts on a large scale to ramp up diagnostics and testing. The lead author is Steve Webb, chief executive officer of the Global Institute for Food Security (GIFS) at the University of Saskatchewan. Webb will explain how the tools used in plant breeding—like genetic testing and sequencing, are the same as those use in the pharmaceutical and health care fields.The Canadian Beef Industry Conference usually attract hundreds of cattle producers, as well as the other players in the beef industry to Calgary, Alberta. But instead the conference was held entirely on-line due to COVID-19. The opening keynote speaker was from London, England. David Hughes is an Emeritus Professor of Food Marketing at Imperial College. He is considered an expert in global food issues and opportunities. He spoke about food trends and the steps the cattle industry needs to take in order to be sustainable and strong.See omnystudio.com/listener for privacy information.

Speech Language Pathology: Continuing Education Courses by SLP Nerdcast Course Title: Mental Health and Supervision: Perspectives on Supervision of Graduate StudentsGet .1 ASHA CEU and view the full course landing page: https://courses.slpnerdcast.com/courses/mental-health-and-supervision-perspectives-on-supervision-of-graduate-students-abje0123Earning Speech-Language Pathology CEUs Online is Simplified with SLP Nerdcast. On SLP Nerdcast you'll find SLP Continuing Education Courses, Masterclasses and Clinical Resources. To learn more about our services visit ▶ https://bit.ly/SLPNERDCAST To learn more about our membership and save 10% on your first year of membership visit ▶ https://bit.ly/SLPNerdcastMembership use code “YouTubeNerd” to save.Learning Objectives:Describe practices that support the mental health needs of graduate studentsDescribe Anderson's continuum and how feedback changes throughout the clinical education processIdentify at least 6 characteristics of effective feedbackReferences & Resources:Evans, T.M., Bira, L., Gastelum, J.B., Wiss, L.T., & Vanderford, N.L. (2018). Evidence for a mental health crisis in graduate education. Nature Biotechnology, 36, 282-284.Gonzalo, J. D., Heist, B. S., Duffy, B. L., Dyrbye, L., Fagan, M. J., Ferenchick, G., Harrell, H., Hemmer, P. A., Kernan, W. N., Kogan, J. R., Rafferty, C., Wong, R., & Elnicki, M. D. (2014). Content and timing of feedback and reflection: A multi-center qualitative study of experienced bedside teachers. BMC Medical Education, 14(1).​Lara, Mogensen, & Markuns. (2016). Effective Feedback in the Education of Health Professionals. Support Line. 38(2); 3-8.​Lieberman, R., Raisor-Becker, L, Sotto C., & Redle, E. (2018). Investigation of Graduate Student Stress in Speech Language Pathology. Teaching and Learning in Communication Sciences and Disorders. 2(2) Article 6.Malandraki, J. (2022 November 21) From My Perspective/Opinion: The Cost of Overlooking Mental Health in Graduate Education. ASHA LeaderLive. https://leader.pubs.asha.org/do/10.1044/leader.FMP.26052021.8/full/McCready, V., Raleigh, L., Schober-Peterson, D., & Wegner, J. (2016). Feedback: What's new and different? Perspectives of the ASHA Special Interest Groups, 1(11), 73–80. ​Nottingham & Henning. (2014) Feedback in Clinical Education, Part I: Characteristics of Feedback Provided by Approved Clinical Instructors. Journal of Athletic Training. 49(1); 49-57.​Nottingham & Henning. (2014) Feedback in Clinical Education, Part II: Approved Clinical Instructor and Student Perceptions of and Influences on Feedback. Journal of Athletic Training. 49(1); 58-67. ​Nunes, P., Williams, S., Sa, B., Stevenson, K., (2011) A Study of Empathy decline in students from five health disciplines during their first year of training. International Journal of Medical Education. 2; 12-17.Ramani, S & Krackov, SK. (2012). Twelve tips for giving feedback effectively in the clinical environment. Medical Teacher. 34; 787-791. ​Rice, S. (2017) Stress and the Surfboard. The ASHA Leader. 22(6).Rizzolo, D. & Massey, S., (2020) Fluctuations in STress Over Time During the First Year of Health Science Programs. Journal of Allied Health. 49(2); 120-124.Tilstra, J., Coffman, M., Gonia, T., Koziol, C., Liebe, E. (2019). Communication Sciences and Disorders Graduate Students' Strengths and Vulnerabilities Related to Resilience: A Survey of Graduate Programs. The Internet Journal of Allied Health Sciences and Practice. Walden, P. R. & Gordon-Pershey, M. (2013). Applying Adult Experiential Learning Theory to Clinical Supervision: A Practical Guide for Supervisors and Supervisees. Perspectives on Administration and Supervision. 23(3); 121-144.Weiland, D., & Kucirk, B. (2020) Helicopter Parenting and the Mental Health of iGen College Students. Journal of Psychosocial Nursing & Mental Health Services. 58(5); 16-22.Zylla-Jones, E. (2009). Feedback in Supervision. ASHA – Perspectives on Administration and Supervision. 19-24.

A quick snippet on Antonio Camargo and Simon Roux, a few of the JGI researchers behind software that finds plasmids and viruses within microbial genomes. As mobile genetic elements like viruses spread their DNA, they can affect how microbes cycle nutrients and adapt to climate change.Episode TranscriptPublication: Camargo, A.P., et al. “Identification of mobile genetic elements with geNomad,” Nature Biotechnology. (2023). doi: 10.1038/s41587-023-01953-yScience Highlight: You can move, but you can't hideLearn more about geNomad and download itSubmit your own proposal to work with the JGIExplore IMG/VR and IMG/PROur contact info:Twitter: @JGIEmail: jgi-comms at lbl dot gov

Daniel Hashimoto is an assistant Professor of Surgery at the Hospital of the University of Pennsylvania, USA. Dan has developed multiple computer vision algorithms for the analysis of surgical video, led international consensus on defining ground truth for the annotation of surgical video, and worked to define metrics to assess performance of AI algorithms on surgical tasks. His work has been published in the New England Journal of Medicine, Nature Biotechnology, Annals of Surgery, and other journals. He is editor of the textbook Artificial Intelligence in Surgery: Understanding the Role of AI in Surgical Practice. He is also heavily involved in MICCAI society with a focused attention to CLINICCAI.

Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations. Guests: Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society. Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.

Steve Harvey and his business partner managed to raise enough money to rent some lab space in Cambridge (UK) to get started on an idea they had for synthesizing template-free DNA. The StartThey invited an investor to meet them at the lab where they sat on the garden furniture Steve brought with him because they had nothing else.TL;DR They got more money. Camena Bioscience was getting started.That was the first hurdle. There were more. Competitors had similar ideas around the IP. And evolution had a different idea, altogether. Synthesizing DNA without a template means providing an enzyme with modified nucleotide bases so that only one can be added to the DNA chain at a time. After addition, a blocking group is removed, allowing the next base in the sequence to be added. That's the only way to end up with the gene you intend to make. The problem is that most enzymes are very good at what they do. In this case, the enzyme, terminal deoxynucleotidyl transferase, naturally prefers unmodified nucleotides (evolution). If there are any of those contaminating the mix, the enzyme will add a string of them even before you can spell “DNA”. The end result is likely a lot of DNA of the wrong sequence.The PivotSteve decided it was time to take a different approach. (If you meet a founder who has never had to pivot, congratulate them.) It's a hard thing to do after investing time and money and being (partially) successful.The new approach seems to have worked out. Camena published a couple of application notes and they were picked up by Nature Biotechnology for a story about DNA synthesis technologies.Now they were getting customers but awareness was still a challenge.I had a couple of people that came to me and said, “We've looked at your website. We, don't really know what you do.” Okay. And so I decided that we need to get some kind of numerical value on brand awareness. I announced the team, “We're gonna run some brand awareness surveys. We'll put it out via LinkedIn and Twitter as well. We'll understand, you know, do people really know what we do?” And I put it out and I was quite excited about doing this. And then I think it was two weeks later, we'd had five responses. And I think one of the responses was from a family member. So, so it didn't go very well.But Steve wasn't deterred. He tried again with the offer of a $25 Amazon gift card. I think it was within a week we had 2000 responses. So it was, the whole thing was really funny. But what came out of that was that, it was roughly kind of 75% of people that responded to the survey had only heard of us in the last six months, and we'd been going for nearly like six years!Hey, that's progress.The StorySteve decided to post regularly on LinkedIn about his journey, which is how I found him. He did a great job of posting a little bit of the story each day, (like Charles Dickens!) and teasing what was to come.His followers have grown significantly and no doubt more people know about Camena Bio as a result.In my own experience, authentic personal stories get the most traction. People are interested in people. Products are useful. People are fascinating. You may not think you are, but I've interviewed hundreds of people across several podcasts for myself and my clients. Only one was an absolute dud that left me with nothing to publish.Find your channel. It might be LinkedIn, your blog, a podcast, someone else's podcast or that thing that was Twitter yesterday, but is apparently “X” today.Schedule a 15-minute chat with Chris about turning conversations into content for your life science company.Intro Music stefsax / CC BY 2.5 This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

The Global Ecological Crisis That We're Facing Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers#EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org.  She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Dr. David R. Liu is the Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. In addition, he is the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, Resonance Medicine, and Nvelop Therapeutics. David's research integrates components of biological evolution with chemistry to enable the development of new types of therapeutics and to better study biology. Through chemistry, they can change the structure of a molecule in order to change its function in anticipated ways. They also harness the power of cycles of natural selection to evolve molecules with desired tailor-made properties. Outside of science, David's hobbies include photography, making wooden vessels using a wood lathe, growing bonsai trees, and exploring electronic art and other homemade art projects. He enjoys blending creativity and intellectual pursuits to create something surprising and beautiful. He completed his undergraduate education at Harvard College, majoring in chemistry. He was awarded his PhD in organic chemistry from UC Berkeley, and he joined the faculty at Harvard University afterwards. He has been an HHMI investigator since 2005. Over the course of his career, David has received numerous awards and accolades, including being named the 2022 King Faisal Prize Laureate in Medicine and receipt of the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society David Perlman Award, ACS Chemical Biology Award, the American Chemical Society Pure Chemistry Award, the Arthur Cope Young Scholar Award, and other prestigious awards for his research and teaching. In 2016 and 2020, he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and he was named one of Nature's 10 researchers in 2022. In addition, he is an elected Member of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. In this interview, David shares more about his life and science.

The Person Who Is Not A Scientist, Not A Doctor, And Yet In Many Ways Directing Global Health Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son. To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Why Bill Gates Encourages Farmers To Use Corporate Seed And Fertilizers That Go With Them Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

When you purchase an item after clicking a link from this post, we may earn a commission.Devin: What do you see as your superpower?Paul: I'm not sure I have a superpower, but I think if I if I have a superpower, it's I love to learn. Throughout my career—I tell people who think about getting a PhD, “What's the best thing about the career is you can change careers without changing jobs.” I have looked at, over the course of my career, how businesses earn long-term profits, why some are sustainable over time—in terms of pure profitability. I've looked at poverty. I've looked at strategic risk. Now I'm looking at sustainability. These are all different careers, and I get to do it without ever changing jobs. But the key is you got to keep learning. One of the things I did about 15 or 16 years ago was set a goal to read 30 books that year because I'd ordered a bunch of books. As a professor, I'm like an addict. Amazon is like my best friend. So I thought, I'm going to read 30 books because I have this shelf full of books that I never read. I did it, and I learned a ton. What I've done over the last 15 years is probably averaged 20 to 30 books a year about all sorts of different things. So, on my way home from Minneapolis on Sunday, I read Daniel Yergin's new book, The New Map, which is all about energy driving the world in the 21st century. And then I read David Baldacci's book, one of his novels. I'm also reading a book right now about the future of money and what is digital currency going to be. So, I read promiscuously. I don't draw lines about what I'll read and what I won't read, but I read a lot, and that gives you a different perspective on the world. So, I think my superpower would be I know how to learn, and I love it, and I love to learn new things and try new things.BYU Professor Paul Godfrey was a guest on the show last to talk about his book More than Money: Five Forms of Capital to Create Wealth and Eliminate Poverty. Eliminating poverty is one of my favorite topics and a goal I share with many of you; I think we can see the end of poverty in my lifetime.So, when Paul reached out to share his new book, Clean: Lessons from Ecolab's Century of Positive Impact, covering one of my other favorite topics, I was excited to have him back on the show.AI Summary* Paul Godfrey, the 2022 outstanding faculty member at BYU's Business School and author of Clean: Lessons from Ecolab's Century of Positive Impact, was interviewed on the Superpowers for Good show.* Godfrey's book explores Ecolab's principles of sustainability and how other organizations can adopt them.* The key principles are respect and integration.* Godfrey sees his superpower as loving to learn and reading 20-30 books a year on various topics.* In the interview, he discusses his book and the importance of a love of learning in personal and professional growth.* He offers insights on how to develop a passion for learning, including admitting a lack of knowledge, being willing to go deep, and engaging with experts.* The interview concludes with information on how to purchase the book and connect with Godfrey.Guest-Provided ProfilePaul C. Godfrey (he/him)William and Roceil Low Professor of Business Strategy, Godfrey & AssociatesAbout Godfrey & Associates: Godfrey & Associates is a strategy consulting practice that helps individuals and organizations thrive in an uncertain and challenging world.  About BYU: Brigham Young University is a privately-owned major University that provides a full range of educational and development opportunities for students.Biographical Information: Paul C. Godfrey, the William and Roceil Low Professor of Business Strategy at the BYU Marriott School of Business, received the school's Outstanding Faculty Member award in 2022. His research has appeared in a number of premiere outlets, including Nature Biotechnology, and the Academy of Management Review. He has authored two textbooks, one about Strategy and one on Ethics in Business, and has written three other books. His 2020 book Strategic Risk Management: New tools for competitive advantage in an uncertain world helps executives and leaders understand, monitor, and manage the risks and opportunities central for strategic success. His latest book is Clean: Lessons from Ecolab's Century of Positive Impact, which shows leaders the pathway to contributing to a more sustainable world.Paul received his MBA and PhD degrees from the University of Washington and a Bachelor of Science from the University of Utah. Paul and his wife, Robin, live in Salt Lake City, where they enjoy cooking, hiking, reading, and spending time with their five children and one grandchild. Linkedin: linkedin.com/in/paulcgodfrey Get full access to Superpowers for Good at devinthorpe.substack.com/subscribe

For almost 30 years, the protein KRAS has been the "undruggable target" of cancer research.  Gene mutations in KRAS are responsible for 33% of all human cancers, including pancreatic, lung, and colon cancer.A new molecule identified by Dr. Bhairavi Tolani, an assistant professor at the University of California, San Francisco  upends conventional concepts of directly targeting the protein KRAS as a treatment strategy. Instead she suggests an alternative avenue for treatment of these deadliest cancers.Read her original research in Nature Biotechnology here: https://doi.org/10.1038/s41587-022-01386-z

The Pesticide Treadmill Is A Serious Concern For The Environment  Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Welcome to Neurocareers, the podcast that proves the impossible is possible! We're thrilled to bring you the second episode of our BCI Award Neurocareers series featuring Prof. Nicholas Opie, the mastermind behind the revolutionary Stentrode and endovascular neural interfaces. Prof. Opie, a biomedical engineer and the founding CTO of Synchron, knows what it takes to succeed in the innovative field of neurotech. Prof. Opie's Stentrode project won 1st place in the International BCI Award competition in 2021. In this podcast episode, he'll share his top tips for winning the International BCI Award and building a successful career in the industry. Join us as we dive deep into the Stentrode revolution and discover how endovascular neural interfaces are changing the game. Prof. Opie will take us through his groundbreaking research and share insights on making the impossible possible in neurotech. As always, Neurocareers inspires and educates you on the exciting and ever-evolving world of neuroscience and neurotechnologies. Don't miss this opportunity to learn from one of the best in the field! This BCI Award Neurocareers series is a partnership between Milena Korostenskaja, PhD at the Institute of Neuroapproaches, and Christoph Guger, PhD at g.tec biomedical engineering. About the Podcast Guest: Professor Nicholas Opie, BE BSc PhD MBA, is a leading biomedical engineer and an expert in neural interfaces. He currently serves as the Laboratory Head of the Vascular Bionics Laboratory in the Department of Medicine at the University of Melbourne, where he is also an NHMRC Research Fellow. Throughout his career, Prof Opie has brought multiple biomedical devices from concept to clinic, including a suprachoroidal retinal prosthesis (bionic eye) that aims to restore vision to individuals with profound vision loss, and a motor neuron prosthesis (bionic spine) that seeks to restore independence, communication, and mobility to individuals with paralysis. He has published over 55 peer-reviewed journal articles, including in Nature Biomedical Engineering and Nature Biotechnology. Additionally, he has filed over 90 patents and was awarded the 2021 NFMRI John Raftos AM Award for Advancing Innovation. Prof Opie is also Synchron's founding Chief Technology Officer (CTO), a neural interface company based in Melbourne and New York. He has raised over AUD$210M in private funding and grants and designed Synchron's flagship product, the Stentrode™. The Stentrode is listed in Time Magazine's Top 100 Inventions of 2021 and aims to provide treatment for debilitating medical illnesses while empowering patients by reconnecting them online in ways that dramatically improve their lives. Following a successful first-in-human trial conducted in Australia on the Stentrode motor neuroprosthesis, Prof Opie and Synchron recently received approval from the US FDA. This approval paves the way for a trial in the US, which will commence this year and represents a significant step towards the first FDA approval for implantable brain-computer interfaces. To learn more about Prof Opie and his work, visit his profile page at the University of Melbourne: https://findanexpert.unimelb.edu.au/profile/430403-nicholas-opie. You can also check out the Stentrode SWITCH study, which involved four patients: https://pubmed.ncbi.nlm.nih.gov/36622685/. Learn more about Synchron's innovative technology on their website: https://synchron.com/. Finally, connect with Prof Nicholas Opie on LinkedIn: https://www.linkedin.com/in/professor-nicholas-opie-4603289a/. About the podcast host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume and cover letter development, and interview preparation Access to a network of professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

In this episode of ACM ByteCast, Bruke Kifle hosts a Pat Pataranutaporn, technologist and researcher at the Massachusetts Institute of Technology (MIT). There, he explores the intersection of synthetic virtual humans and synthetic biology, specifically at the interface between biological and digital systems. He is currently a PhD candidate at the Fluid Interfaces Group at the MIT Media Lab and a KBTG Fellow. Pat's research has been published in Nature Machine Intelligence, Nature Biotechnology, IEEE, ACM SIGCHI, ACM SIGGRAPH, ACM ISWC, ACM Augmented Humans, Royal Society of Chemistry, among others. He also serves as a reviewer and editor for IEEE and ACM publications. Pat's published research is recognized worldwide and has been featured in the United Nations AI for Good forum, Time magazine, Forbes, National Geographic, FastCompany, The Guardian, Disruptive Innovation Festival, and more. In the interview, Pat describes how his early fascination with dinosaurs led him into the scientific realm, and later to the MIT Media Lab, where people are encouraged to think about future challenges rather than just focusing on solving current problems. He explains the research area of fluid interfaces and describes some of the innovative work his group has been doing on human-AI co-reasoning. Pat and Bruke also about the future potential of AI in education and wearable devices, as well as MIT's recent space exploration initiative. Pat also offers his perspectives on art and innovation, identifies the exciting new directions currently holding his attention, and offers advice for young people interested in the field of computing.

Episode SummaryThe expression of genes in our genome to produce proteins and non-coding RNAs, the building blocks of life, is critical to enable life and human biology. So, the ability to predict how much of a gene is expressed based on that gene's regulatory DNA, or promoter sequence, would help us both understand gene expression, regulation, and evolution, and would also help us design new, synthetic genes for better cell therapies, gene therapies, and other genomic medicines in bioengineering.However, the process by which gene transcription is regulated is incredibly complex; thus, prediction transcriptional regulation has been an open problem in the field for over half a century. In his work, Eeshit used neural networks to predict the levels of gene expression based on promoter sequences. Then, he reverse engineered the model to design specific sequences that can elicit desired expression levels. Eeshit's work developing a sequence-to-expression oracle also provided a framework to model and test theories of gene evolution.About the GuestEeshit earned his double major in CS & Engineering and Biological Sciences & Engineering from the Indian Institute of Technology in Kanpur. During his PhD at MIT, working on Dr. Aviv Regev's team, he published 4 papers in Nature-family journals, including 2 on the cover and 1 on the cover as first and corresponding author. Eeshit's work is in Cell, Nature Biotechnology, Nature Medicine, Nature Communications, and beyond.Key Takeawayscis-regulatory elements like promoters interact with transcription factors in the cell to regulate gene expression.Variation in cis-regulatory elements drives phenotypic variation and influences organismal fitness.Modeling the relationship between promoter sequences and their function – in this case, the expression levels they induce – is important to better understand regulatory evolution and also enable the engineering of regulatory sequences with specific functions with applications across therapeutics and cell-based biomanufacturing.By cloning 50 million sequences into a yellow fluorescent protein (YFP) expression vector in S. cerevisiae and measuring the YFP levels they induced, Eeshit generated a rich dataset to map yeast promoter sequence to expression levels.Next, Eeshit trained neural network models, including convolutional neural networks and Transformers, to predict expression from sequence with high accuracy.Eeshit then “reverse-engineered” these convolutional models to create genetic algorithms that designed sequences which could induce desired expression levels.Finally, Eeshit's sequence-to-expression oracle allowed for the computational evaluation of regulatory evolution across different evolutionary scenarios, including genetic drift, stabilizing selection, and directional selection.ImpactEeshit's work developing a sequence-to-expression oracle provided a framework to model and test theories of gene evolution.This framework can help us both understand gene expression, regulation, and evolution, and design new, synthetic genes for better cell therapies, gene therapies, and other genomic medicines in bioengineering.Paper: The evolution, evolvability and engineering of gene regulatory DNA 

What Are The Propaganda Campaigns Of The Four Companies Who Now Own Most Of The Seeds And Pesticides? Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

GE Foods Regulation - The U.S. Way Fernanda Santos, PhD, Teaching Assistant Professor, Food Science, NC State University Website | Twitter @fbnsncstate Abstract "The definition of food law used to be a simple one – it encompassed food regulatory law with two main audiences: lawyers and the regulated food industries. Today, however, food law is often broadened in meaning to include all law related to agricultural trade, such as how food is grown, humane animal treatment, and environmental rules for farms and processors." (From Food Regulation by Neal Fortin) The development of genetically engineered foods created an even greater (and heated) discussion linked to several complex issues, especially safety in terms of consumption and the understanding of their impact on the environment. So, the question is: "How should these foods be regulated?" The United States takes a more relaxed approach compared to the strict rules of the European Union. Despite the differences, the final goal is the same: ensuring that foods entering the markets are safe for consumption. This presentation will summarize the main characteristics of the regulation of genetically engineered foods in the United States. Related links: Fortin, N. Food Regulation: Law, Science, Policy, and Practice. Wiley, 2nd. ed., 2022. Roberts, M.T. Food Law in the United States. Cambridge University Press, 2015. Strauss, S., Sax, J. Ending event-based regulation of GMO crops. Nature Biotechnology, 34, 474–477 (2016). https://doi.org/10.1038/nbt.3541 BE Disclosure | USDA Biotechnology | USDA How GMOs Are Regulated in the United States | FDA Movement of Certain Genetically Engineered Organisms – Final Rule | Federal Register “Natural” Modifications: The FDA's Need to Promulgate an Official Definition of “Natural” that Includes Genetically Modified Organisms | The George Washington Law Review Regulation of Biotech Plants | USDA Revised Regulations (previously SECURE Rule) | USDA Same Science, Different Policies: Regulating Genetically Modified Foods in the U.S. and Europe | Harvard University What's the Right Way to Regulate Gene-Edited Crops? | Leaps.org Speaker Bio Dr. Fernanda Santos is a veterinarian, poultry scientist, and food safety specialist. During her veterinary training, her primary focus was zoonotic diseases and disease prevention. Then, she focused her work on pathogen growth in foods of animal origin, quality control programs, and molecular tools. She has also studied alternative methods and nutritional strategies to improve performance and reduce Salmonella intestinal colonization in poultry. Currently, at NC State, her focus is food safety and course development. She is responsible for the graduate food safety minor and teaching several courses in the food science program, including food laws and regulations and food product development. She has also created a new series of courses, “The Discover Series”, which are food science-related courses that are taught not only to food science/nutrition students but also to any undergraduate student who seeks to understand the science behind foods and controversial topics of food and nutrition. GES Colloquium (GES 591-002) is jointly taught by Drs. Jen Baltzegar and Dawn Rodriguez-Ward, who you may contact with any class-specific questions. Colloquium will generally be live-streamed via Zoom, with monthly in-person meetings in the 1911 Building, Room 129. Please subscribe to the GES newsletter and Twitter for updates. Genetic Engineering and Society Center GES Colloquium - Tuesdays 12-1PM (via Zoom) NC State University | http://go.ncsu.edu/ges-colloquium GES Mediasite - See videos, full abstracts, speaker bios, and slides https://go.ncsu.edu/ges-mediasite Twitter - https://twitter.com/GESCenterNCSU GES Center - Integrating scientific knowledge & diverse public values in shaping the futures of biotechnology. Find out more at https://ges-center-lectures-ncsu.pinecast.co

Is The Digitization Of Farms Better For Our Health? Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org

The Cascading Crisis Of The Food System Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers#EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org.  She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

A Fight Over The Fundamental Building Blocks Of Life And Feeding People Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers  #EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org. She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Artigo publicado na Nature Biotechnology apresenta uma espécie de super penso rápido que cura feridas profundas 25% mais rápido.

Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable. This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin. It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home. Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living. Timeline: 02:20 - Esmeralda's background and how it led to the creation of Xsensio 09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform 13:51 - The applications where the Lab-on-Skin(c) platform will play a role 17:28 - The functioning of the Lab-on-Skin(c) platform and its components 22:50 - What lies ahead of Xsensio before making its first product commercialized 28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data 29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty What we also talked about with Esmeralda: Fitbit Apple Watch Bill & Melinda Gates Foundation Lab for Youth Mental Health NANOLAB Veri Supersapiens C-reactive protein Troponin T Mayo Clinic Rea Diagnostics We cited with Esmeralda some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter. As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing. You can get in touch with Esmeralda through LinkedIn or by email: esmeralda.megally@xsensio.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don't hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!

New 2022 - The Future of Food Bill Gates and Agtech vs Agroecology and Food Sovereignty- Stacy Malkan Stacy Malkan • https://usrtk.org/• Book - Not Just a Pretty Face #StacyMalkan #CosmeticDangers#EnvironmentalHealthIssues Stacy Malkan is co-founder and managing editor of U.S. Right to Know, a nonprofit investigative research group focused on promoting transparency for public health usrtk.org.  She began working on environmental health issues in 2001 and has researched food and agriculture, with a focus on agrichemical industry misinformation campaigns, since 2012.Stacy is author of the award-winning book, Not Just a Pretty Face: The Ugly Side of the Beauty Industry. The book  Is a The girls' guide to giving the cosmetics industry a makeover.Lead in lipstick? 1,4 dioxane in baby soap? Coal tar in shampoo? How is this possible?Simple. The $35 billion cosmetics industry is so powerful that they've kept themselves unregulated for decades. Not one cosmetic product has to be approved by the US Food and Drug Administration before hitting the market. Incredible? Consider this: The European Union has banned more than 1,100 chemicals from cosmetics. The United States has banned just 10.Only 11% of chemicals used in cosmetics in the US have been assessed for health and safety – leaving a staggering 89% with unknown or undisclosed effects.More than 70% of all personal care products may contain phthalates, which are linked to birth defects and infertility.Many baby soaps are contaminated with the cancer-causing chemical 1,4 dioxane. It's not just women who are affected by this chemists' brew. Shampoo, deodorant, face lotion and other products used daily by men, women and children contain hazardous chemicals that the industry claims are "within acceptable limits." But there's nothing acceptable about daily multiple exposures to carcinogenic chemicals-from products that are supposed to make us feel healthy and beautiful. Not Just a Pretty Face delves deeply into the dark side of the beauty industry and looks to hopeful solutions for a healthier future. This scathing investigation peels away less-than-lovely layers to expose an industry in dire need of an extreme makeover.Stacy Malkan is also a co-founder of the Campaign for Safe Cosmetics, a coalition of health groups that exposed hazardous chemicals in nail polish, baby products, make-up and hair products and pressured companies to reformulate to safer products. Her work has been published in Time magazine, New York Times, Washington Post, Nature Biotechnology and many other outlets. She has appeared in Teen Vogue, Good Morning America, Wall Street Journal, San Jose Mercury News, San Francisco Chronicle, Democracy Now! and documentary films including The Human Experiment produced by Sean Penn, Pink Skies and Stink Movie (now playing on Netflix). Stacy was media director for the California Right to Know ballot initiative to label genetically engineered foods.For eight years, she served as communications director for Health Care Without Harm, an international coalition of health groups working to transform health care, so it is no longer a source of environmental harm. Prior to that role, she worked for a decade as a journalist, editor, and newspaper publisher in Colorado. She now lives in the California Bay Area with her husband and son.To Contact Stacy Malkan go to usrtk.org CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:  https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Dr. Caplan is currently the Drs. William F. and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU Grossman School of Medicine in New York City. Prior to coming to NYU, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. He has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics; the University of Pittsburgh; and Columbia University. He received his PhD from Columbia University. Dr. Caplan is the author or editor of 35 books and more than 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy (MIT Press, 2017, with Jason Schwartz) and Getting to Good: Research Integrity in Biomedicine (Springer, 2018, with Barbara Redman). He has served on a number of national and international committees including as chair of the National Cancer Institute Biobanking Ethics Working Group; chair of the Advisory Committee to the United Nations on Human Cloning; and chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses; the Special Advisory Committee to the International Olympic Committee on Genetics and Gene Therapy; the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects; the Wellcome Trust Advisory Panel on Research in Humanitarian Crises; and as the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. Dr. Caplan has served since 2015 as a chair of the Compassionate Use Advisory Committees (CompAC), independent groups of internationally recognized medical experts, bioethicists, and patient representatives that advise Johnson & Johnson's Janssen Pharmaceuticals on requests for compassionate use of its investigational medicines. Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City, and CNN. He appears frequently as a guest and commentator on various other national and international media outlets. Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year” and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine. During the COVID-19 pandemic, he is co-directing an advisory group on sports and recreation for the U.S. Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, and helped develop rationing policies for NYU Langone Health and many other health systems. He is a member of the WHO advisory committee on COVID-19, ethics, and experimental drugs/vaccines, and he helped set policy for WIRB/WCG for research studies. He was an adviser to Moderna, Inc., and he serves on the NCAA COVID-19 Medical Advisory Group. Dr. Caplan received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014, he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016, the National Organization for Rare Disorders (NORD) honored him with its Rare Impact Award; that year he also received the Food and Drug Law Institute's Distinguished Service Leadership Award and the American Society for Bioethics and Humanities' Lifetime Achievement Award. In 2019, he was honored by the Reagan-Udall Foundation for the FDA with its Innovation Award. Dr. Caplan's faculty page: https://med.nyu.edu/faculty/arthur-l-caplan Dr. Caplan holds seven honorary degrees from colleges and medical schools. Dr. Caplan's electronic long-form (ELF) disclosure statement can be found here: https://bit.ly/3ilyprJ Dr. Caplan's twitter address: https://twitter.com/arthurcaplan?s=21&t=RLCoVC9ZUsFtn5g_mllyxw COI disclosures. https://bit.ly/3eixl7l Working Group on Compassionate Use and Preapproval Access (CUPA) https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-compassionate-use-preapproval-access Vaccine Working Group on Ethics and Policy http://vaccineworkinggroupethics.org/ Working Group on Pediatric Gene Therapy & Medical Ethics https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/working-group-pediatric-gene-therapy-medical-ethics Transplant Ethics and Policy https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/research/transplant-ethics-policy  

Dr. Encarnita Mariotti-Ferrandiz is associate professor in Immunology at Sorbonne Université, Paris, France. Encarnita is Chair-Elect of the AIRR-Community. The discussion focuses on sample quality and how to assess this. We draw on two papers during the discussion: “Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases” (Nature Biotechnology; 2021; https://doi.org/10.1038/s41587-020-0656-3) and “Biological controls for standardisation and interpretation of adaptive immune receptor repertoire profiling” (eLife; 2021;  https://doi.org/10.7554/eLife.66274). iReceptor Plus Seminar Series - Xiaole Shirley Liu from Dana-Farber Cancer Institute and Jeff Ruffolo from Johns Hopkins University will present on September 22, 2022: https://www.ireceptor-plus.com/news-and-events/seminars  The episode is hosted by Dr. Ulrik Stervbo and Dr. Zhaoqing Ding. Comments are welcome to the inbox of onairr@airr-community.org or on social media under the hashtag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast

Go to mindyourownrevisions.com to learn more about how I help fellow academics to prevent and overcome burnout as well as maintain mental and emotional wellbeing, and sign up for my newsletter to receive more resources.**********************************************************According to the publication from 2018 by Evans et al. in Nature Biotechnology, 41% of graduate students meet the criteria for moderate to severe anxiety and 39% of graduate students meet the criteria for moderate to severe depression. This is, compared to 6% of the general population.We are battling with a pandemic of mental health and burnout in academia. The problem is very obvious, but what can we do to be a part of the solution?Here are some ideas to get you started. Hosted on Acast. See acast.com/privacy for more information.

Jay Keasling is a professor in the College of Chemistry at the University of California at Berkeley, where he runs the Keasling lab. He's also the CEO of the Joint BioEnergy Institute, and has been involved in several startups. His conversation with Nature Biotechnology covers growing up on the family farm in Nebraska, how Genentech led him into biotech, and the future of biofuels. See acast.com/privacy for privacy and opt-out information.

To go along with my investigative story The CRISPR Children in Nature Biotechnology, I am producing a rolling series of podcasts. This episode is a chat with Dr. Eben Kirksey, an anthropologist at Deakin University, which has campuses in and near Melbourne, Australia. He has written a book called The Mutant Project, Inside the Global Race to Genetically Modify Humans.  It's dedicated to Lulu and Nana, two of the three children who are known to have had their genomes edited before their birth. Their birth in 2018 caused a global uproar. there is also a third child, whom I call Amy, who also has a gene-edited genome. Dr. Kirksey talks about the lab that brought them about and offers some background about the social, political, cultural aspects that made the experiments possible. 

The CRISPR Children is a podcast series about the children whose genomes were edited before their birth in 2018. The podcasts accompany a story I did about these children in Nature Biotechnology by the same name. You can find the story here: https://rdcu.be/cB7Nx  The children were born somewhere in China. They came about due to experiments performed in the lab of He Jiankui at Southern University of Science and Technology in Shenzhen. These were unethical experiments. How are the children? And how could you assess their health and possible future risks? And why are they genetically mosaic? There is a lot of secrecy and rumor about these children. One has to maintain their privacy and dignity. They are celebrities and victims. They and their parents might be helped if the biomedical community tried to understand more about the experiments. But that is far from straightforward. Especially because many scientists declined to talk about them. But a number of them kindly did speak with me and I am grateful for that. Here is some of what I heard.       

The CRISPR Children is a series of podcasts about the children whose genomes were edited before their birth in 2018. The podcasts accompany a story I did about these children in Nature Biotechnology by the same name. You can find the story here: https://rdcu.be/cB7Nx  The children were born somewhere in China and the result of experiments performed in the lab of He Jiankui at Southern University of Science and Technology in Shenzhen. These were unethical experiments. But how are the children? And how could you assess their health and possible future risks? There is a lot of secrecy and rumor about these children. One has to maintain their privacy and dignity, of course. But they are also victims. They and their parents might be helped if the biomedical community tried to understand more about the experiments. But that is far from straightforward. Especially because many scientists declined to talk about them. But a number of them kindly did speak with me and I am grateful for that. Here is some of what I heard.  This episode is with Dr Kiran Musunuru of the University of Pennsylvania, a physician-scientist who works in genetics and gene-editing. He has also co-founded a company called Verve Therapeutics. He has written a book about the children called: The CRISPR generation The Story of the World's First Gene-Edited Babies.

Todd Zipper, President of Wiley Education Services, welcomes Bob Ubell, Vice Dean Emeritus of Online Learning at NYU's Tandon School of Engineering & Senior Advisor to Stevens Institute of Technology. Todd and Bob discuss the effects of the COVID-19 pandemic on online learning and the future of digital education. Topics Discussed: • The shift in attitude, from pre-pandemic to now, on the efficiency of online learning • How online, digital education will be crucial for universities long-term • How online learning is shifting from a faculty-centered learning model to an active learning model • The need for university leadership to devote the same energy to online programs as their on-campus programs Guest Bio Bob Ubell is Vice Dean Emeritus of Online Learning at NYU's Tandon School of Engineering and Senior Advisor to Stevens Institute of Technology. Considered an expert of digital education, he consults for universities and edtech companies including Coursera, NYU, and The New School and his online programs have enrolled more than 30,000 students. For almost a decade, he headed Tandon Online, ranked #2 by US News & World Report of the nation's Computer Information Technology online graduate programs.  Bob has also taken his expertise overseas. In China, he headed three online master's programs and was a member of the board of the Lianyungang Universal Vehicle Manufacturing Company. In London, he served as American Publisher of Nature, the prominent science weekly, and launched the journal, Nature Biotechnology. Bob has contributed nearly 90 articles to scholarly and general periodicals, is a columnist for EdSurge, a contributor for Inside Higher Ed, and is the author or editor of 20 books. His most recent book, Staying Online: How to Navigate Digital Higher Education, was released in September 2021. 

Hamdi is the Executive Director of AVX, a non-profit cooperative exchange connecting high-value talent with early start-ups backed with research and IP from leading comprehensive research universities across the United States. AVX focuses on solving the 'talent valley of death' for deep technology ventures. Over the past 4 years, AVX has worked with over 520 proto-ventures from 33 different universities and has generated over 10,000 connections for these teams with advisors, board members, co-founders, c-level leaders, and investors who have experience helping inventors build ventures. This conversation is a fast-paced, deep dive into the world of technology transfer. Hamdi has seen and participated in this sector from a variety of different vantage points and has an extremely unique perspective. We talk about the team DNA of strong research-based university spinoff companies, including advice to young entrepreneurs and researchers who want to lead or join these initiatives. Hamdi is one of the most well-connected people in the space and operates at a distinctive intersection and critical stage for these young startups coming out of the lab. We talk about what tech transfer orgs (TTOs) do well, how they can improve, and also Hamdi's background as a researcher and what might be on the horizon for him. I always learn from Hamdi every time we speak and this was no exception. I highly recommend signing up for Hamdi's newsletters which aggregates an enormous amount of useful info on research commercialization from around the web including articles, insights, events and more. See past issues here and enjoy the episode! More about Hamdi Prior to AVX, Hamdi completed his BA/BS in Chemical Engineering at Tufts University and his PhD at Columbia University in the lab of Dr. Ozgur Sahin. Hamdi's research interests lie at the intersection of biology, energy, and the environment; his thesis is titled “A Theory of Renewable Energy from Natural Evaporation”. Hamdi has co-authored several papers in Nature Biotechnology and Nature Communications. During his PhD, Hamdi served as the President of the Graduate Student Advisory Council at Columbia University and worked for 6 years as a Fellow (3 years) and Senior Fellow (3 years) at Columbia Technology Ventures – the tech transfer office at Columbia University in the City of New York. Hamdi previously served as an assistant and advisor to both the BioMedX Accelerator at Columbia University and the New York City Regional Innovation Node (NYCRIN) of the National Science Foundation (NSF) i-Corps program. Find Hamdi on LinkedIn. Learn more about AVX on their website. Join the Bountiful community today and realize your power to save the world. Don't forget to follow us on Twitter and LinkedIn if you haven't already.

Dr. Hayden Metsky begins the episode by describing his goal of being able to harness sequenced viral genomes to computationally design diagnostics, therapies, and vaccines. He discusses the value of having methods available that can handle all available genomic data for diverse species for diagnostics and therapies. Next, we learn how CRISPR can be used in a diagnostics setting. Dr. Metsky explains how collateral cleavage broadens the use of CRISPR beyond simply being a tool for genome editing. Advantages and disadvantages of CRISPR-based diagnostics techniques are discussed versus, for example, a more traditional qPCR approach. The discussion then moves on to the computational component of the diagnostics design problem. Dr. Metsky discusses his 2019 Nature Biotechnology paper on the CATCH method for use in hybridization capture and his progression of work in this area (see https://www.nature.com/articles/s41587-018-0006-x). Finally, we discuss his work in designing diagnostics for SARS-CoV-2, CRISPR-based tests being able to gain widespread adoption, and expanding this work beyond viruses to include bacteria as well.

Nature Biotechnology's Irene Jarchum speaks with Michel Sadelain about off-the-shelf CAR-T cells, and discusses a recent paper from Maksim Mamonkin's group describing a clever strategy to mitigate CAR-T cell rejection. The paper was published in Nature Biotechnology and can be read here. See acast.com/privacy for privacy and opt-out information.

Jennifer Doudna and David Liu talk with our Senior Editor Markus Elsner about the state of the genome editing field and what challenges remain, especially as various therapies are now entering the clinic. This episode is part of Nature Biotechnology's Focus issue on CRISPR tools and therapies. See acast.com/privacy for privacy and opt-out information.

A recent Nature Biotechnology paper from Tony Atala and colleagues at Wake Forest describes the use of bioengineered scaffolds to repair substantial injuries to rabbit uteri, supporting pregnancies and live births. Senior Editor Irene Jarchum discusses this work with Mats Brännström and Mats Hellström, both from Gothenburg University in Sweden. You can read the paper here. See acast.com/privacy for privacy and opt-out information.

近期一组遗传学家宣布了成功创造能够产生可见光的植物，他们在某些菇类中发现的生物发光在代谢上类似于植物中常见的自然过程，因此他们构思通过插入从蘑菇中获得的DNA，创造出比以前亮，且持续发光的植物。这一发现公布在Nature Biotechnology杂志上。由27位科学家撰写，其中Karen Sarkisyan博士和Ilia Yampolsky主导研究。

Senior editor Irene Jarchum talks to Cliona Rooney about a recent paper in which Mark Cobbold and colleagues describe an antibody-mediated strategy to re-target virus-specific T cells against tumors. The paper was published in Nature Biotechnology; it can be read here. See acast.com/privacy for privacy and opt-out information.

Brady Huggett talks with Zemin Zhang about a recent Nature Biotechnology paper detailing the use of spatial transcriptomics in providing new insights into tumor architecture. The work was done by Itai Yanai and co-authors, and the paper can be read here. See acast.com/privacy for privacy and opt-out information.

Senior Editor Irene Jarchum talks to Stefan Schneeberger about the significance of a recent Nature Biotechnology paper describing a sophisticated perfusion machine to keep human livers alive for a week. The work was carried out by Pierre-Alain Clavien and colleagues from ETH Zurich. Read the paper here. See acast.com/privacy for privacy and opt-out information.

The power of the payer in the biopharmaceutical industry has increased dramatically over the past several years, according to Keith Kelly, Managing Director and Head of the Pricing and Market Access Practice of inVentiv Health Consulting. Market access was once a dull topic. Today, price and if a drug will be covered is discussed on earnings calls and in the board room. What payers do can make or break the stock price of a company overnight. In this episode, Kelly and host Jeff Stewart discuss what factors have contributed to the payer's rise in influence; how payers are wielding this power; why drug price negotiation is similar to discount suit shopping; and the “prisoner's dilemma” of acquiring access for products entering the market at the same or similar time. The pair also explores the nirvana concept of “sustainable market access” – is it even possible? – and the value creation equation for a pharmaceutical company looking to achieve it for their products. Data from this episode originated from the following sources: Gross to net pricing from Credit Suisse; manufacturing cost analysis published in the Journal of Pharmaceutical Innovation and Nature Biotechnology; and Hepatitic C drug costs covered in Reuters. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.